查詢結果分析
相關文獻
頁籤選單縮合
題 名 | Immunomodulatory Therapy in Refractory/Recurrent Ovarian Cancer |
---|---|
作 者 | Chen, Chao-yu; Lai, Chyong-huey; Yang, Lan-yan; Tang, Yun-hsin; Chou, Hung-hsueh; Chang, Chee-jen; Lin, Cheng-tao; | 書刊名 | Taiwanese Journal of Obstetrics & Gynecology |
卷 期 | 54:2 2015.04[民104.04] |
頁 次 | 頁143-149 |
分類號 | 417.25 |
關鍵詞 | Epithelial ovarian cancer; Immunomodulatory therapy; Recurrence; |
語 文 | 英文(English) |
英文摘要 | OBJECTIVE: To investigate the efficacy and toxicity of immunomodulatory therapy (IMT) alone or as an add-on to palliative/salvage chemotherapy in patients with refractory/recurrent epithelial ovarian cancer (EOC). MATERIALS AND METHODS: We retrospectively analyzed the efficacy and toxicity of IMT in 15 patients with refractory/recurrent EOC who had previously received multiple chemotherapy regimens. RESULTS: The median age of the patients was 56 years (range, 41-75 years). Three patients were platinum-sensitive, two were platinum-resistant, and the remaining 10 patients were refractory to platinum-based front-line chemotherapy. IMT consisted of picibanil (OK-432) on Day 1, interleukin-2 and/or interferon-α on Day 2 administered by subcutaneous injection (every week or 2-weekly). Five patients never received metronomic oral cyclophosphamide. After IMT, three patients achieved partial remission (PR, lasting for 11 months, ≥ 12 months, and 16 months), and six patients had stable disease (SD). The disease stabilizing rate (PR+SD) was 60% (3/3 in platinum-sensitive and 6/12 in platinum-resistant/refractory patients). The absolute lymphocyte count (ALC) at 1 month after IMT was significantly higher in the PR+SD group (median 1242.0/μL) than in the progression group (median 325.0/μL) (p = 0.012). No ≥ Grade 3 toxicities were observed. The median post-IMT survival time was 12 months (range, 2-39 months). CONCLUSION: IMT alone or add-on to palliative/salvage chemotherapy for refractory/recurrent EOC achieves a substantial disease stabilizing rate without severe toxicity, which might be a potential option in selected patients. The ALC 1 month after IMT could be an early indicator to disease stabilization. |
本系統中英文摘要資訊取自各篇刊載內容。